News

Sweden launches testbed for clinical trials in cancer care

Vision Zero Cancer and Genomic Medicine Sweden (GMS) join forces with SciLifeLab, public sector authorities, regions, healthcare, academia, industry and patient organizations to create an innovation milieu that facilitates the introduction of more precise prevention...

Significant nationwide investment in precision medicine

The Swedish national infrastructure Genomic Medicine Sweden (GMS) will receive an additional SEK 220 million investment. The investment will facilitate the continued introduction of precision medicine into Swedish healthcare, so that every individual in Sweden has...

Precision medicine new opportunity for complex diseases

New review article looks at readiness prior to the implementation of genomics-based precision medicine in complex diseases. The extensive work has been led by researchers at Karolinska Institutet and Lund University and has been carried out together with some 30...

GMS’s ambitions for the next 10 years

Genomic Medicine Sweden (GMS) highlights vital aspects for the successful introduction of precision medicine into Swedish healthcare in its Strategy Plan 2021–2030. In Strategy Plan 2021–2030, GMS presents its ambitions for the introduction of precision medicine into...

Report from the first meeting with the GMS Scientific Advisory Board

The Scientific Advisory Board, SAB, is impressive about GMS ‘rapid development and the enormous work that GMS has accomplished. But emphasizes the importance of a formal national leadership structure and lists five important strategic recommendations for further...

Bettina Lundgren new member of GMS Scientific Advisory Board

Bettina Lundgren, CEO of the Danish National Genome Center, has recently joined the GMS Scientific Advisory Board. “We welcome Bettina Lundgren to our Scientific Advisory Board and look forward to sharing experiences between the Swedish and Danish initiatives”, said...